Navigation Links
Data Published in Plastic and Reconstructive Surgery Show Cohera Medical's Surgical Adhesive, TissuGlu(R), Prevents Seroma Formation in Animal Abdominoplasty Model
Date:6/19/2008

PITTSBURGH, June 19 /PRNewswire/ -- Cohera Medical Inc. today announced that data published in the July issue of Plastic and Reconstructive Surgery show the company's surgical adhesive, TissuGlu, was effective in preventing the formation of seroma in an animal abdominoplasty model.

Summarized in a paper titled "Lysine-Derived Urethane Surgical Adhesive Prevents Seroma Formation in a Canine Abdominoplasty Model," (Plast. Reconstr. Surg. 2008; Vol. 122, Issue 1: 95-102) the results demonstrated that TissuGlu successfully prevented the formation of seroma in a novel large-animal model designed to evaluate seroma formation. While the control side in all seven animals used in the study demonstrated large, clinically significant seromas, the side treated with TissuGlu showed little or no evidence of fluid accumulation. In addition, histologic analysis of tissue samples from the animals showed no signs of inflammation or foreign body reaction associated with the adhesive.

"I am impressed with the experimental data that demonstrate a clear ability of the adhesive to control seroma formation in this animal model," said J. Peter Rubin, M.D., founder and director of the Life After Weight Loss surgical body contouring program at the University of Pittsburgh and the lead author of the paper. "This adhesive shows strong potential for widespread applications in many surgical specialties."

Surgeons have expressed a strong need for a product that adheres tissue flaps to help prevent the fluid accumulation that occurs between tissue layers after surgery. Surgical adhesives available today fall into two categories: "superglue"-type products that are strong but cannot be used inside the body because they break down into toxic byproducts and "fibrin sealant" products that are biocompatible but create a weak bond and are expensive and difficult to prepare during surgery.

"Seromas have been a major problem for post-surgical patients," said Susan E. Downey, M.D., a board-certified plastic surgeon at the Pacific SurgiCenter in Santa Monica, Calif. "This study demonstrates a great animal model and the efficacious use of an adhesive to address this difficult problem."

"The results illustrate the potential efficacy of TissuGlu and helps support the movement of TissuGlu into human clinical studies, which we expect to initiate next year," said Patrick Daly, president and CEO of Cohera Medical. "Our goal is to introduce to surgeons a tissue adhesive that encompasses the desired strong and effective bonding properties in a safe, resorbable and easy-to-use formulation."

Seroma formation is a frequent complication of plastic surgery procedures such as abdominoplasty, with complication rates ranging from 15 percent to 52 percent. In 2007, approximately 148,000 abdominoplasty, or "tummy tuck," procedures were performed in the United States, according to the American Society of Plastic Surgeons.

About Cohera Medical

Cohera Medical Inc. is a Pittsburgh-based company that is developing a revolutionary line of wound management products and surgical adhesives. Cohera Medical's products are based on a unique chemical design that is purely synthetic, easy to use, biocompatible and fully resorbable. The company's lead product in development, TissuGlu, is a sprayable bonding agent for plastic surgery procedures. TissuGlu adheres flaps of tissue after surgical procedures, eliminating the spaces where fluid accumulates and reducing wound drainage. Cohera Medical is also developing surgical adhesives targeting mesh fixation and small bone fixation, which will fill similar market needs in both orthopedics and general surgery. For more information, visit http://www.coheramed.com. TissuGlu and the other Cohera products have not yet been approved for medical use by the Food and Drug Administration (FDA) in the US or by any other country's regulatory authority.

Certain statements made throughout this press release that are not historical facts contain forward-looking statements regarding the Company's future plans, objectives and expected performance. Any such forward-looking statements are based on assumptions that the Company believes are reasonable, but are subject to a wide range of risks and uncertainties and, therefore, there can be no assurance that actual results may not differ materially from those expressed or implied by such forward-looking statements.


'/>"/>
SOURCE Cohera Medical Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Long-term safety data on Lialda published in leading GI journal
2. Long-Term Safety Data on Lialda(TM) (mesalamine) for Patients With Ulcerative Colitis Published in Leading GI Journal
3. New Regulations for Hospice Provision Published by CMS
4. First Comprehensive Reference on Evidence-Based Design Published
5. Premier issue of Environmental Justice just published
6. Safe Options for Cardiac Lead Removal: Study Published in Heart Rhythm Journal
7. Castle Connollys Long Islands Top Doctors Published in Newsday Generates More Than 1.1 Million Views of Top Doctors Profiles in Single Day
8. Northfield Laboratories Inc. Comments on Article and Editorial on Hemoglobin-Based Blood Substitutes to be Published in May 21 JAMA
9. 20th Edition of the Encyclopedia of Social Work Published
10. Clinical guidelines for the manual titration of PAP in OSA patients published in JCSM
11. Bradmer announces Phase II results published in newly diagnosed glioblastoma which demonstrate improved survival and support upcoming Phase III study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/18/2017)... ... 18, 2017 , ... Mediaplanet today announces the launch of ... and highlighting the importance of proactive eye and ear health. The campaign focuses ... innovations in hearing aid technology. , In this issue, the National Association ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... ... liquid handling handheld devices. Through an educational webinar, they will present the line ... a chance to learn how easy you can automate everyday pipetting tasks. , ...
(Date:8/18/2017)... , ... August 18, 2017 , ... ... services and asset protection assistance to communities in North-Central West Virginia, is embarking ... services to at-risk boys in the area. , The Chestnut Mountain Ranch (CMR) ...
(Date:8/18/2017)... (PRWEB) , ... August 18, 2017 , ... The Brian ... in northwest Indiana, is campaigning in support of Campagna Academy in a charity drive ... as the “Hoosier Boys’ Town of Indiana,” Campagna Academy is a nonprofit organization that ...
(Date:8/18/2017)... ... August 18, 2017 , ... “Emotions are sacred, valid, honored, ... St. Louis-based positive education company Generation Mindful. To help change the mindset of parents ... and emotional skills, she created the Time-In Toolkit, which launched on Kickstarter 3 weeks ...
Breaking Medicine News(10 mins):
(Date:8/2/2017)... AURORA, Ore. , Aug. 2, 2017  Life Flight ... Call Agreement. The agreement improves patient care and operational efficiency ... Springfield , Cottage Grove ... ICU level medical transportation. PeaceHealth and Life Flight Network work ... care available during transport, or when a time sensitive emergency ...
(Date:7/31/2017)... Mich. , July 31, 2017  Diplomat Pharmacy, Inc. ... in southeast Michigan by Crain,s ... ranks private and public companies by three-year revenue growth. This ... To view the complete list, visit ... Fast 50 is an incredible triumph," said Phil Hagerman ...
(Date:7/28/2017)... Hill-Rom Holdings, Inc. ("Hill-Rom") (NYSE: HRC), today announced financial ... 2017, and updated its financial outlook for fiscal 2017. ... fiscal third quarter, Hill-Rom reported earnings of $0.09 per ... the prior-year period. These results reflect after-tax special items, ... related to the non-cash write-down of assets associated with ...
Breaking Medicine Technology: